There is an increasing need to both publish and find reliable information with reproducible knowledge, which can be translated into practice. Thus, we, a group of professionals and lead scientists (see Directors), decided to create our own scientists-led non-profit publishing company and founded Andover House Inc. (ANHI) in January 2018. ANHI is a not-for-profit publisher registered in the Commonwealth of Massachusetts, USA.
Aims and scope of Andover House Inc. is to provide good quality and supportive publishing forum with quick turnaround time for nanomedicine researchers and offer a cutting-edge and reliable information source to societies, libraries, and the interested public without additional cost.
Our objective is to disseminate peer-reviewed scientific reports and individual articles online in academic journals that are open to the scientific community and accessible by the public without additional charge to readers and libraries.
Our mission is further the progress of science, engineering, and technology in medicine and promote all progressive and rational aspects of nanomedicine from basic science through commercialization while exercising good publishing practice.
We support authors who wish to share their work early through deposition of manuscripts with preprint servers such as bioRxiv or arXiv, have previously been presented at conferences, published as a thesis, or have previously appeared in other “non-journal” venues (for example blogs or posters). Authors are responsible for updating the archived preprint with the journal reference (including DOI) and a link to the published articles on the appropriate journal website upon publication.
All articles receive a unique identifier and are archived in Portico for preservation. Article DOI-s may be searched in Crossref and DOAJ. We are members of COPE, and of DOAJ, our green archiving policy is registered in Sherpa/Romeo‘s, so either preprint or post-print PDFs (as well as Publisher’s versions) can be archived, without restrictions.
The Publisher is governed by the Board of Directors, which oversees operations, approves the annual budget, and sets strategic goals for the organization. We are supported by the European Foundation for Clinical Nanomedicine (CLINAM.org), the International Society for Nanomedicine (https://www.clinam.org/eur-int-society-for-nanomedicine.html), and by the European Society for Nanomedicine (http://www.esnam.org).
NOTE: We are signatories of the San Francisco Declaration on Research Assessment. We advise against the use of journal-based metrics, such as Journal Impact Factors, as a surrogate measure of the quality of individual research articles, to assess an individual scientist’s contributions, or in hiring, promotion, or funding decisions. We support article-based metrics and follow the publication policies of WHO.